Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | integrin beta 2 | 0.1156 | 0.7229 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0164 | 0.0431 | 0.0444 |
Echinococcus granulosus | nicotinic acetylcholine receptor alpha subunit | 0.0197 | 0.0659 | 0.0336 |
Brugia malayi | Kelch motif family protein | 0.0237 | 0.0934 | 0.0758 |
Loa Loa (eye worm) | hypothetical protein | 0.0129 | 0.019 | 0.019 |
Loa Loa (eye worm) | kelch domain-containing protein family protein | 0.0237 | 0.0934 | 0.0934 |
Brugia malayi | nicotinic acetylcholine receptor alpha subunit, putative | 0.0197 | 0.0659 | 0.0478 |
Loa Loa (eye worm) | hypothetical protein | 0.0237 | 0.0934 | 0.0934 |
Echinococcus multilocularis | nicotinic acetylcholine receptor subunit alpha 8 | 0.0197 | 0.0659 | 0.0336 |
Loa Loa (eye worm) | hypothetical protein | 0.0178 | 0.0527 | 0.0527 |
Loa Loa (eye worm) | integrin beta-2 | 0.156 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0598 | 0.3407 | 0.3407 |
Brugia malayi | hypothetical protein | 0.0237 | 0.0934 | 0.0758 |
Schistosoma mansoni | integrin alpha-ps | 0.0178 | 0.0527 | 0.0623 |
Echinococcus granulosus | integrin alpha ps | 0.0341 | 0.1649 | 0.1792 |
Echinococcus granulosus | nicotinic acetylcholine receptor a11 subunit | 0.0197 | 0.0659 | 0.0336 |
Schistosoma mansoni | integrin beta subunit | 0.0919 | 0.5605 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.042 | 0.2189 | 0.2189 |
Loa Loa (eye worm) | hypothetical protein | 0.0129 | 0.019 | 0.019 |
Echinococcus granulosus | nicotinic acetylcholine receptor subunit alpha 8 | 0.0197 | 0.0659 | 0.0336 |
Echinococcus multilocularis | integrin alpha 3 | 0.0584 | 0.331 | 0.4236 |
Brugia malayi | Integrin alpha cytoplasmic region family protein | 0.0576 | 0.3257 | 0.3126 |
Echinococcus granulosus | microtubule associated protein 2 | 0.0669 | 0.3896 | 0.5098 |
Schistosoma mansoni | microtubule-associated protein tau | 0.0669 | 0.3896 | 0.6845 |
Loa Loa (eye worm) | integrin alpha pat-2 | 0.1174 | 0.7355 | 0.7355 |
Echinococcus granulosus | integrin beta 2 | 0.1156 | 0.7229 | 1 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.0762 | 0.4529 | 0.4422 |
Loa Loa (eye worm) | nicotinic acetylcholine receptor alpha subunit | 0.0197 | 0.0659 | 0.0659 |
Loa Loa (eye worm) | hypothetical protein | 0.0197 | 0.0659 | 0.0659 |
Echinococcus granulosus | integrin alpha 3 | 0.0584 | 0.331 | 0.4236 |
Loa Loa (eye worm) | hypothetical protein | 0.0576 | 0.3257 | 0.3257 |
Brugia malayi | follicle stimulating hormone receptor | 0.0232 | 0.0898 | 0.0721 |
Echinococcus multilocularis | integrin alpha ps | 0.0341 | 0.1649 | 0.1792 |
Onchocerca volvulus | Putative nachr subunit | 0.0197 | 0.0659 | 1 |
Loa Loa (eye worm) | follicle stimulating hormone receptor | 0.0232 | 0.0898 | 0.0898 |
Schistosoma mansoni | integrin alpha | 0.0762 | 0.4529 | 0.8013 |
Echinococcus multilocularis | integrin alpha ps | 0.0341 | 0.1649 | 0.1792 |
Echinococcus multilocularis | nicotinic acetylcholine receptor a11 subunit | 0.0197 | 0.0659 | 0.0336 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0669 | 0.3896 | 0.5098 |
Echinococcus multilocularis | nicotinic acetylcholine receptor alpha subunit | 0.0197 | 0.0659 | 0.0336 |
Schistosoma mansoni | integrin alpha-ps | 0.0341 | 0.1649 | 0.2694 |
Loa Loa (eye worm) | hypothetical protein | 0.0164 | 0.0431 | 0.0431 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 ratio (functional) | = 2 | In vitro effect of the compound on microtubule assembly relative to that of Taxol, expressed as ED50/ED50 (Taxol=1) | ChEMBL. | No reference |
ED50 ratio (functional) | = 20.7 | In vitro effect of the compound on B16 melanoma cytotoxicity relative to that of Taxol, expressed as ED50/ED50 (Taxol=1) | ChEMBL. | No reference |
ID50 ratio (binding) | = 2 | Binding affinity to microtubules, activity expressed as ID50 of compound/ID50 of paclitaxel | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.